Companies: 10,795·Total market cap: $144.5T
LeMaitre Vascular, Inc.

LeMaitre Vascular, Inc.

LMATNASDAQHealthcare● Active
$94.21
$-0.27(-0.29%)
Market Cap$2.2B
P/E Ratio
52W High$118.01
52W Low$79.01

LeMaitre Vascular, Inc. (LMAT) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

lmat · stock forecast · 20 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 20 Wall Street analysts in the past 3 months

SellBuy

Buy

20 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
14
Hold
6
Sell
0
Strong Sell
0
Total: 20 · Buy rate: 70.0%

12-Month Price Target

High

$135

Consensus

$128

+36.1% upside

Low

$120

Median: $127.5 · Last Close: $93.68

The LeMaitre Vascular, Inc. (LMAT) analyst consensus is Buy, based on ratings from 20 Wall Street analysts over the past 3 months. The average 12-month LMAT price target is $127.50, representing +36.1% upside from the current price of $93.68.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $128 (36.1%)

Consensus Target

$127.50

36.1% upside

High Target

$135

44.1%

Low Target

$120

28.1%

Current Price

$93.68

as of today

Based on analyst price targets, the LMAT stock price prediction for the next 12 months ranges from $120 to $135. The consensus LMAT price forecast of $127.50 implies 36.1% upside from the current price of $93.68.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$91.392.45%

1-day model range: $91.01–$91.77. Peak: $91.77 (-2.45%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$125+33.8%
2028$151+60.9%
2029$169+80.5%
2030$181+93.6%
2031+102.1%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

21%0%79%
3Buy
0Neutral
11Sell
RSI (14)28.5Oversold
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · LMAT · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$93.00BUY
MA 10$94.00SELL
MA 20$96.74SELL
MA 50$105.58SELL
MA 100$101.04SELL
MA 200$94.43SELL
Current $LMAT · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$93.62BUY
EMA 10$94.55SELL
EMA 20$97.38SELL
EMA 50$101.40SELL
EMA 100$100.24SELL
EMA 200$96.41SELL
Current $LMAT · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Barrington Research2026-06-03
Maintains
OutperformOutperform
Barrington Research2026-05-06
Maintains
OutperformOutperform
Wells Fargo2026-05-06
Maintains
Equal WeightEqual Weight
Citizens2026-05-06
Maintains
Market OutperformMarket Outperform
Citizens2026-02-26
Maintains
Market OutperformMarket Outperform
Barrington Research2026-02-26
Maintains
OutperformOutperform
Roth Capital2026-02-26
Maintains
BuyBuy
Wells Fargo2026-02-26
Maintains
Equal WeightEqual Weight
Barrington Research2026-02-20
Maintains
OutperformOutperform
Wells Fargo2025-11-07
Maintains
Equal WeightEqual Weight

Wall Street analysts have recently issued updated ratings on LeMaitre Vascular, Inc. (LMAT) stock. Of the recent 73 rating actions, 8 were upgrades and 9 were downgrades. 20 analysts currently cover LMAT.

Analyst Recommendation Trends

Buy ratings11
Hold ratings00
Sell ratings00

LMAT analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$248M

↓ 18.9% YoY

Revenue Next Year

$280M

↑ 12.9% YoY

EPS This Year

$2.46

EPS Next Year

$3.00

↑ 21.7% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast LMAT EPS of $2.46 for the current fiscal year, based on estimates from 7 analysts. The LMAT revenue forecast is $248M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The LMAT stock forecast is supported by two independent data sources: analyst consensus ratings from 20 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus LMAT price target is $127.50 (+36.1% upside), with an analyst consensus of Buy.

The LMAT short-term stock prediction for tomorrow is $91.39 (-2.45%). The LMAT stock price prediction for 2027 estimates an average of $125. The LMAT stock prediction for 2030 projects a range of $173–$190.

LeMaitre Vascular, Inc. trades on NASDAQ under the ticker LMAT. The LMAT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 70% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

LMAT forecast · 8 questions

According to 20 Wall Street analysts, the average 12-month LMAT price target is $127.50, with a high forecast of $135.00 and a low of $120.00. The median price target is shown in the chart above when available. This implies +36.1% potential upside from the current price of $93.68.

LMAT price targetWhat is LMAT price targetLMAT analyst price targetLMAT 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.